Segment Information - Net Revenue and Segment Ebitda (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Mar. 31, 2022	Mar. 31, 2021	Mar. 31, 2022	Mar. 31, 2021
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		$ 1,273.0	$ 1,053.0	$ 3,515.0	$ 2,810.0
Inter-segment revenue elimination		(4.0)	(6.0)	(15.0)	(12.0)
Segment Reporting Information Unallocated Expense	[1]	(54.0)	123.0	(211.0)	49.0
Biologics
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		698.0	544.0	1,882.0	1,325.0
Segment EBITDA		216.0	180.0	579.0	422.0
Softgel and Oral Technologies
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		324.0	244.0	896.0	711.0
Segment EBITDA		75.0	59.0	194.0	143.0
Oral and Specialty Drug Delivery
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		154.0	171.0	456.0	500.0
Segment EBITDA		41.0	31.0	118.0	97.0
Clinical Supply Services
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Net revenue		101.0	100.0	296.0	286.0
Segment EBITDA		30.0	27.0	83.0	77.0
Total Catalent sub-total of Segment Reporting [Member]
Segment Reporting, Revenue & EBITDA Reconciling Item [Line Items]
Segment EBITDA		$ 362.0	$ 297.0	$ 974.0	$ 739.0

[1] Unallocated costs include restructuring and special items, stock-based compensation, gain on sale of subsidiary, impairment charges, certain other corporate directed costs, and other costs that are not allocated to the segments as follows: